Rapid induction of complete molecular remission by sequential therapy with LDAC and sorafenib in FLT3-ITD-positive patients unfit for intensive treatment: Two cases and review of the literature

Journal of Hematology and Oncology

Volumn 6, Issue 1, 2013, Pages

  Wolleschak, Denise ^a   Schalk, Enrico ^a   Krogel, Christian ^a   Schnoeder, Tina M ^a   Luehr, Helga ^a   Jentsch Ullrich, Kathleen ^b   Fischer, Thomas ^a   Heidel, Florian H ^a  

^a OTTO VON GUERICKE UNIVERSITY   (Germany)

^b Pract of Hematol and Int Oncology   (Germany)

Author keywords

AML; LDAC; Small molecule; Sorafenib; Targeted therapy

Indexed keywords

CYTARABINE; HEMOGLOBIN; MEROPENEM; SORAFENIB;

ACUTE GRANULOCYTIC LEUKEMIA; ADULT; AGED; ANEMIA; ANTIBIOTIC THERAPY; AORTA VALVE STENOSIS; APHASIA; ARTICLE; BONE MARROW BIOPSY; BONE MARROW CELL; CANCER CHEMOTHERAPY; CANCER PALLIATIVE THERAPY; CANCER PATIENT; CANCER REGRESSION; CANCER SURVIVAL; CAROTID ARTERY; CASE REPORT; CELL REGENERATION; CELL STRUCTURE; CEREBROVASCULAR ACCIDENT; COMPLETE MOLECULAR REMISSION; CONGESTIVE HEART FAILURE; DIABETES MELLITUS; ECHOCARDIOGRAPHY; EOSINOPHIL; ERYTHROCYTE TRANSFUSION; FEBRILE NEUTROPENIA; FEMALE; FITNESS; GENE MUTATION; HEART INFARCTION; HEART LEFT VENTRICLE HYPERTROPHY; HEMATOPOIESIS; HEMIPLEGIA; HOSPITAL ADMISSION; HUMAN; HUMAN CELL; HYPERLIPOPROTEINEMIA; HYPERTENSION; INDUCTION CHEMOTHERAPY; INTENSIVE CARE; LEFT HEMISPHERE; LEUKOCYTE COUNT; LEUKOCYTOSIS; LEUKOPENIA; LYMPHOCYTE; MEDICAL HISTORY; MITRAL VALVE STENOSIS; MULTIPLE CYCLE TREATMENT; NEUTROPHIL; OBESITY; PANCYTOPENIA; PATIENT REFERRAL; PHYSICAL MEDICINE; POLYMERASE CHAIN REACTION; REHABILITATION CENTER; SMOKING; SYSTOLIC HEART MURMUR; THROMBOCYTE; THROMBOCYTE TRANSFUSION; THROMBOCYTOPENIA; TREATMENT RESPONSE;

AGED; ANTIBODY SPECIFICITY; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CYTARABINE; FEMALE; FMS-LIKE TYROSINE KINASE 3; HUMANS; LEUKEMIA, MYELOID, ACUTE; LYMPHOCYTES; MIDDLE AGED; NIACINAMIDE; PHENYLUREA COMPOUNDS; PROGNOSIS; REMISSION INDUCTION;

EID: 84878740465     PISSN: None     EISSN: 17568722     Source Type: Journal    
DOI: 10.1186/1756-8722-6-39     Document Type: Article

References (30)

1. A double-blind placebo-controlled trial of granulocyte colony-stimulating factor in elderly patients with previously untreated acute myeloid leukemia: a southwest oncology group study (9031). Godwin JE, Kopecky KJ, Head DR, Willman CL, Leith CP, Hynes HE, Balcerzak SP, Appelbaum FR, Blood 1998 91 3607 3615 9572995 (Pubitemid 28225726)
2. Attempts to improve treatment outcomes in acute myeloid leukemia (AML) in older patients: the results of the United Kingdom medical research council AML11 trial. Goldstone AH, Burnett AK, Wheatley K, Smith AG, Hutchinson RM, Clark RE, Blood 2001 98 1302 1311 10.1182/blood.V98.5.1302 11520775
3. Mitoxantrone versus daunorubicin in induction-consolidation chemotherapy-the value of low-dose cytarabine for maintenance of remission, and an assessment of prognostic factors in acute myeloid leukemia in the elderly: final report. European organization for the research and treatment of cancer and the Dutch-Belgian hemato-oncology cooperative hovon group. Lowenberg B, Suciu S, Archimbaud E, Haak H, Stryckmans P, de Cataldo R, Dekker AW, Berneman ZN, Thyss A, van der Lelie J, et al. J Clin Oncol 1998 16 872 881 9508168 (Pubitemid 28115455)
4. The cancer and leukemia group B: intensive postremission chemotherapy in adults with acute myeloid leukemia. Mayer RJ, Davis RB, Schiffer CA, Berg DT, Powell BL, Schulman P, Omura GA, Moore JO, McIntyre OR, Frei E, N Engl J Med 1994 331 896 903 10.1056/NEJM199410063311402 8078551 (Pubitemid 24299870)
5. Influence of new molecular prognostic markers in patients with karyotypically normal acute myeloid leukemia: recent advances. Mrozek K, Dohner H, Bloomfield CD, Curr Opin Hematol 2007 14 106 114 10.1097/MOH.0b013e32801684c7 17255787 (Pubitemid 46175094)
6. Cytogenetics in acute leukemia. Mrozek K, Heerema NA, Bloomfield CD, Blood Rev 2004 18 115 136 10.1016/S0268-960X(03)00040-7 15010150 (Pubitemid 38380667)
7. Prognostic relevance of integrated genetic profiling in acute myeloid leukemia. Patel JP, Gonen M, Figueroa ME, Fernandez H, Sun Z, Racevskis J, Van Vlierberghe P, Dolgalev I, Thomas S, Aminova O, et al. N Engl J Med 2012 366 1079 1089 10.1056/NEJMoa1112304 22417203
8. Mutations and treatment outcome in cytogenetically normal acute myeloid leukemia. Schlenk RF, Dohner K, Krauter J, Frohling S, Corbacioglu A, Bullinger L, Habdank M, Spath D, Morgan M, Benner A, et al. N Engl J Med 2008 358 1909 1918 10.1056/NEJMoa074306 18450602 (Pubitemid 351620111)
9. Prognostic significance of activating FLT3 mutations in younger adults (16 to 60 years) with acute myeloid leukemia and normal cytogenetics: a study of the AML Study Group Ulm. Frohling S, Schlenk RF, Breitruck J, Benner A, Kreitmeier S, Tobis K, Dohner H, Dohner K, Blood 2002 100 4372 4380 10.1182/blood-2002-05-1440 12393388 (Pubitemid 35434129)
10. The impact of FLT3 internal tandem duplication mutant level, number, size, and interaction with NPM1 mutations in a large cohort of young adult patients with acute myeloid leukemia. Gale RE, Green C, Allen C, Mead AJ, Burnett AK, Hills RK, Linch DC, Blood 2008 111 2776 2784 10.1182/blood-2007-08- 109090 17957027
11. Analysis of FLT3-activating mutations in 979 patients with acute myelogenous leukemia: association with FAB subtypes and identification of subgroups with poor prognosis. Thiede C, Steudel C, Mohr B, Schaich M, Schakel U, Platzbecker U, Wermke M, Bornhauser M, Ritter M, Neubauer A, et al. Blood 2002 99 4326 4335 10.1182/blood.V99.12.4326 12036858 (Pubitemid 34627197)
12. Structural and numerical variation of FLT3/ITD in pediatric AML. Meshinchi S, Stirewalt DL, Alonzo TA, Boggon TJ, Gerbing RB, Rocnik JL, Lange BJ, Gilliland DG, Radich JP, Blood 2008 111 4930 4933 10.1182/blood-2008-01- 117770 18305215
13. Favorable outcome of patients with acute myeloid leukemia harboring a low-allelic burden FLT3-ITD mutation and concomitant NPM1 mutation: relevance to post-remission therapy. Pratcorona M, Brunet S, Nomdedeu J, Ribera JM, Tormo M, Duarte R, Escoda L, Guardia R, Queipo de Llano MP, Salamero O, et al. Blood 2013 121 2734 2738 10.1182/blood-2012-06-431122 23377436
14. An FLT3 gene-expression signature predicts clinical outcome in normal karyotype AML. Bullinger L, Dohner K, Kranz R, Stirner C, Frohling S, Scholl C, Kim YH, Schlenk RF, Tibshirani R, Dohner H, Pollack JR, Blood 2008 111 4490 4495 10.1182/blood-2007-09-115055 18309032
15. Low-dose ara-C in acute nonlymphocytic leukemia and myelodysplastic syndromes: a review of 20 years' experience. Cheson BD, Simon R, Semin Oncol 1987 14 126 133 3589688
16. A comparison of low-dose cytarabine and hydroxyurea with or without all-trans retinoic acid for acute myeloid leukemia and high-risk myelodysplastic syndrome in patients not considered fit for intensive treatment. Burnett AK, Milligan D, Prentice AG, Goldstone AH, McMullin MF, Hills RK, Wheatley K, Cancer 2007 109 1114 1124 10.1002/cncr.22496 17315155 (Pubitemid 46435390)
17. Phase IIB trial of oral Midostaurin (PKC412), the FMS-like tyrosine kinase 3 receptor (FLT3) and multi-targeted kinase inhibitor, in patients with acute myeloid leukemia and high-risk myelodysplastic syndrome with either wild-type or mutated FLT3. Fischer T, Stone RM, Deangelo DJ, Galinsky I, Estey E, Lanza C, Fox E, Ehninger G, Feldman EJ, Schiller GJ, et al. J Clin Oncol 2010 28 4339 4345 10.1200/JCO.2010.28.9678 20733134
18. Results from a randomized trial of salvage chemotherapy followed by lestaurtinib for patients with FLT3 mutant AML in first relapse. Levis M, Ravandi F, Wang ES, Baer MR, Perl A, Coutre S, Erba H, Stuart RK, Baccarani M, Cripe LD, et al. Blood 2011 117 3294 3301 10.1182/blood-2010-08-301796 21270442
19. Sorafenib versus placebo in addition to standard therapy in adult patients ≥60 years with newly diagnosed acute myeloid leukemia: results from the randomized-controlled soraml trial. Rollig C, Muller-Tidow C, Huttmann A, Kunzmann V, Baldus CD, Brandts C, Kramer A, Schafer-Eckart K, Neubauer A, Krause SW, et al. Blood (ASH Annual Meeting Abstracts) 2012
20. Results of a multicenter phase II trial for older patients with c-kit-positive acute myeloid leukemia (AML) and high-risk myelodysplastic syndrome (HR-MDS) using low-dose ara-C and imatinib. Heidel F, Cortes J, Rucker FG, Aulitzky W, Letvak L, Kindler T, Huber C, Dohner H, Kantarjian H, Fischer T, Cancer 2007 109 907 914 10.1002/cncr.22471 17285599 (Pubitemid 46335678)
21. A phase I/II study of sorafenib in combination with low dose cytarabine in elderly patients with acute myeloid leukemia or high-risk myelodysplastic syndrome from the National Cancer Institute of Canada Clinical Trials Group: trial IND.186. Macdonald DA, Assouline SE, Brandwein J, Kamel-Reid S, Eisenhauer EA, Couban S, Caplan S, Foo A, Walsh W, Leber B, Leuk Lymphoma 2013 54 760 766 10.3109/10428194.2012.737917 23061485
22. Phase IB study of PKC412, an oral FLT3 kinase inhibitor, in sequential and simultaneous combinations with daunorubicin and cytarabine (DA) induction and high-dose cytarabine consolidation in newly diagnosed patients with AML. Fischer T, Giles F, Paquette R, Schiller G, Ehninger G, Schiffer C, Cortes J, Kantarjian H, DeAngelo D, Heidel F, Cohen PS, Yu R, Bilic S, Zhang L, Phillips PS, Stone RM, Haematologica 2006 92 (EHA Meeting Abstracts)
23. Sorafenib in combination with standard induction and consolidation therapy in elderly AML patients: results from a randomized, placebo-controlled phase II trial. Serve H, Wagner R, Sauerland C, Blood (ASH Annual Meeting Abstracts) 2010 116
24. Validation of ITD mutations in FLT3 as a therapeutic target in human acute myeloid leukaemia. Smith CC, Wang Q, Chin CS, Salerno S, Damon LE, Levis MJ, Perl AE, Travers KJ, Wang S, Hunt JP, et al. Nature 2012 485 260 263 10.1038/nature11016 22504184
25. Phase I study of sorafenib in patients with refractory or relapsed acute leukemias. Borthakur G, Kantarjian H, Ravandi F, Zhang W, Konopleva M, Wright JJ, Faderl S, Verstovsek S, Mathews S, Andreeff M, Cortes JE, Haematologica 2011 96 62 68 10.3324/haematol.2010.030452 20952518
26. Sorafenib treatment of FLT3-ITD(+) acute myeloid leukemia: favorable initial outcome and mechanisms of subsequent nonresponsiveness associated with the emergence of a D835 mutation. Man CH, Fung TK, Ho C, Han HH, Chow HC, Ma AC, Choi WW, Lok S, Cheung AM, Eaves C, et al. Blood 2012 119 5133 5143 10.1182/blood-2011-06-363960 22368270
27. Compassionate use of sorafenib in FLT3-ITD-positive acute myeloid leukemia: sustained regression before and after allogeneic stem cell transplantation. Metzelder S, Wang Y, Wollmer E, Wanzel M, Teichler S, Chaturvedi A, Eilers M, Enghofer E, Neubauer A, Burchert A, Blood 2009 113 6567 6571 10.1182/blood-2009-03-208298 19389879
28. Survey and analysis of the efficacy and prescription pattern of sorafenib in patients with acute myeloid leukemia. Rollig C, Brandts C, Shaid S, Hentrich M, Kramer A, Junghanss C, Schleyer E, Muller-Tidow C, Berdel WE, Ritter B, et al. Leuk Lymphoma 2012 53 1062 1067 10.3109/10428194.2011.637210 22054287
29. Minimal residual disease based on patient specific Flt3-ITD and-ITT mutations in acute myeloid leukemia. Scholl S, Loncarevic IF, Krause C, Kunert C, Clement JH, Hoffken K, Leuk Res 2005 29 849 853 10.1016/j.leukres.2004.12.001 15921740 (Pubitemid 40779492)
30. Patterns of molecular response to and relapse after combination of sorafenib, idarubicin, and cytarabine in patients with FLT3 mutant acute myeloid leukemia. Al-Kali A, Cortes J, Faderl S, Jones D, Abril C, Pierce S, Brandt M, Kantarjian H, Ravandi F, Clin Lymphoma Myeloma Leuk 2011 11 361 366 10.1016/j.clml.2011.06.007 21816375